Get the app
US › Healthcare

Boundless Bio, Inc. Common Stock (BOLD)

US · Healthcare · Biotechnology

$2.80-0.71%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-23.7M
EPS
$-1.06
EPS estimate
$-0.58

EPS came in at -1.06 against a street estimate of -0.58 — a miss of 82.8%.

Key statistics

Market cap
$64.4M
Forward P/E
0.0
P/B
0.98
Book value
$2.94
EPS (TTM)
$-2.85
52-week high
$3.16
52-week low
$0.96
50-day MA
$2.69
200-day MA
$1.67
Beta
0.44

Analyst view

Analysts rate Boundless Bio, Inc. Common Stock a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $4.00.

Shareholding

Insiders
12.09%
Institutions
67.26%

Largest institutional holders

FundStake
FMR Inc11.85%
ARCH VENTURE CORP11.84%
Stonepine Capital Management Llc2.63%
Vanguard Capital Management, LLC2.63%
Wellington Management Company LLP2.45%
Millennium Management LLC2.10%
Renaissance Technologies Corp1.75%
Alyeska Investment Group, L.P.1.32%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Boundless Bio, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.